

Acid Sequence Disclosures, both of which were mailed July 16, 1998.

In the Communication, the Examiner restricted Applicants to three designated inventions, namely, the invention of Group I (Claims 1, 2, 4-62, drawn to antigen constructs), the invention of Group II (Claims 3, and 63-68, drawn to a polynucleotides, host cells and expression vectors) and the invention of Group III (Claims 69-77, drawn to methods of detection and kits). Applicants hereby elect the invention of Group I, without traverse.

The Examiner also required Applicants to elect one species from the claims, which correspond to the elected invention. Applicants hereby elect from the grouping designated by the Examiner as "b1", species pGO-11PL (corresponding to SEQ ID NO:51).


#### Sequence Listing

Pursuant to the Notice, Applicant provides herewith a substitute paper copy of the Sequence Listing as well as an initial computer readable form copy. A statement to support the filings and submissions in accordance with 37 CFR §1.821-1.825 also accompanies this response. Applicants also provide instructions, in the amendment shown above, as to the placement of the substitute paper copy of the Sequence Listing into the specification. Applicants respectfully submit that the amendment adds no new matter and request entry of the filings and submissions into the record.

Respectfully submitted,

J. R. Hackett *et al.*

ABBOTT LABORATORIES  
D-377, AP6D/2  
100 Abbott Park Road  
Abbott Park, IL 60064-6050  
Telephone: (847)-938-3137  
Facsimile: (847)-938-2623

  
Dianne Casuto  
Registration No. 40, 943  
Attorney for Applicants